Empirical Finance LLC Sells 273 Shares of Edwards Lifesciences Co. (NYSE:EW)

Empirical Finance LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,734 shares of the medical research company’s stock after selling 273 shares during the quarter. Empirical Finance LLC’s holdings in Edwards Lifesciences were worth $1,535,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the 3rd quarter worth $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,000 shares of company stock worth $547,430 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on EW shares. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Trading Down 0.9 %

NYSE EW opened at $70.38 on Monday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average price is $72.45 and its 200-day moving average price is $69.30. The stock has a market cap of $41.51 billion, a P/E ratio of 10.16, a P/E/G ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.